Proulx-Rocray and colleagues (2021) showed that the presence of STK11 and/or KEAP1 mutations was associated with a negative impact on survival when compared with wild-type NSCLC patients treated with immune check point inhibitors (96). This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.